US · ITGR · MEDICAL - DEVICES
Integer Holdings Corporation (ITGR) intrinsic value and stock valuation
$126.97as of 2026-11-21 · Mkt cap 4.24B
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Integer Holdings Corporation DCF and intrinsic value
InvestorsCraft values ITGR with the Chepakovich two-stage DCF model — currently rated strongly overvalued. How the model works · Run your own DCF prefilled from ITGR’s statements →
Integer Holdings Corporation Graham Number
Graham Number: $57.85d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →
How the business is doing
Fiscal 2011–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
- LivaNova PLC (LIVN) $90.73
- Concentra Group Holdings Parent, Inc. (CON) $41.84
- Haemonetics Corporation (HAE) $120.16
- UFP Technologies, Inc. (UFPT) $290.85
- Addus HomeCare Corporation (ADUS) $122.50
- Inspire Medical Systems, Inc. (INSP) $55.10
- Recursion Pharmaceuticals, Inc. (RXRX) $2.45
- Artivion, Inc. (AORT) $18.16
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $1.85B | $1.72B | $1.56B | $1.33B | $1.22B |
| Operating income | $209.3M | $208.2M | $163.3M | $112.7M | $135.7M |
| Net income | $102.8M | $119.9M | $90.7M | $66.4M | $96.8M |
| EPSd | $2.89M | $3.36M | $2.69M | $1.99M | $2.91M |
| Operating cash flow | $196.2M | $205.2M | $180.2M | $116.4M | $156.7M |
| Capital expenditure | -$-91.03M | -$-105.36M | -$-119.94M | -$-74.73M | -$-53.46M |
| Free cash flow | $105.1M | $99.9M | $60.3M | $41.7M | $103.2M |
| Total assets | $3.41B | $3.08B | $2.94B | $2.79B | $2.58B |
| Total debt | $1.4B | $1.1B | $1.05B | $1.01B | $905.8M |
| Net debt | $1.38B | $1.06B | $1.03B | $984.5M | $887.9M |
| Total equity | $1.75B | $1.62B | $1.52B | $1.42B | $1.35B |
| Cash and short-term investments | $17.2M | $46.5M | $23.7M | $24.3M | $17.9M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $1.85B | $1.72B | $1.56B | $1.33B | $1.22B |
| Cost of revenue | $1.42B | $1.26B | $1.14B | $984.6M | $884.1M |
| Gross profit | $425.8M | $461.2M | $411.5M | $346.7M | $337M |
| Research and development expenses | $46.4M | $53.4M | $62M | $59.8M | $52M |
| Selling, general and administrative expenses | $162.6M | $184.3M | $171.5M | $157.4M | $141.7M |
| Other expenses | $7.6M | $15.2M | $14.8M | $16.9M | $7.58M |
| Operating expenses | $216.5M | $253M | $248.2M | $234M | $201.3M |
| Cost and expenses | $1.64B | $1.51B | $1.39B | $1.22B | $1.09B |
| Interest income | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Interest expense | $42.3M | $56.4M | $53.4M | $37.3M | $31.6M |
| Depreciation and amortization | $126M | $109.7M | $97M | $90.9M | $81.6M |
| Ebitda | $293.7M | $332.9M | $275.7M | $221.8M | $224.7M |
| Operating income | $209.3M | $208.2M | $163.3M | $112.7M | $135.7M |
| Total other income/expenses, net | -$-83.87M | -$-60.67M | -$-57.94M | -$-44M | -$-34.65M |
| Income before tax | $125.4M | $147.6M | $105.4M | $68.7M | $101.1M |
| Income tax expense | $22.6M | $26.5M | $16.2M | $8.93M | $8.04M |
| Net income | $102.8M | $119.9M | $90.7M | $66.4M | $96.8M |
| Weighted average shares outstanding | $34.7M | $33.6M | $33.3M | $33.1M | $33M |
| Weighted average diluted shares outstanding | $35.6M | $35.7M | $33.8M | $33.4M | $33.3M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $17.2M | $46.5M | $23.7M | $24.3M | $17.9M |
| Net receivables | $346.1M | $349M | $317.2M | $298.3M | $251.8M |
| Inventory | $253.7M | $247.1M | $229.1M | $208.8M | $155.7M |
| Total current assets | $770.1M | $671.1M | $617.7M | $558.3M | $453M |
| Property, plant and equipment, net | $672M | $579.6M | $501.4M | $400.9M | $347.2M |
| Goodwill and intangible assets | $1.94B | $1.8B | $1.79B | $1.8B | $1.73B |
| Long-term investments | $7.96M | $7.42M | $11.8M | $13.9M | $21.8M |
| Total non-current assets | $2.64B | $2.41B | $2.32B | $2.24B | $2.13B |
| Total assets | $3.41B | $3.08B | $2.94B | $2.79B | $2.58B |
| Accounts payable | $113.1M | $101.5M | $118.3M | $110.8M | $76.9M |
| Short-term debt | $22.1M | $25.7M | $10.9M | $29.6M | $25.1M |
| Deferred revenue | $5.21M | $4.44M | $6.14M | $5.62M | $3.78M |
| Total current liabilities | $232M | $227.2M | $221M | $223.8M | $159.6M |
| Long-term debt | $1.38B | $1.08B | $1.04B | $979.1M | $880.1M |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total non-current liabilities | $1.43B | $1.23B | $1.2B | $1.15B | $1.07B |
| Capital lease obligations | $110.5M | $101.5M | $82.4M | $72.1M | $67.2M |
| Total liabilities | $1.66B | $1.46B | $1.42B | $1.38B | $1.23B |
| Common stock | $40K | $30K | $30K | $30K | $30K |
| Retained earnings | $994.1M | $891.3M | $771.4M | $680.7M | $614.3M |
| Accumulated other comprehensive income (loss) | $58.2M | -$-14.04M | $20.2M | $5.33M | $27.2M |
| Total equity | $1.75B | $1.62B | $1.52B | $1.42B | $1.35B |
| Total investments | $7.96M | $7.42M | $11.8M | $13.9M | $21.8M |
| Total debt | $1.4B | $1.1B | $1.05B | $1.01B | $905.8M |
| Net debt | $1.38B | $1.06B | $1.03B | $984.5M | $887.9M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | $102.8M | $119.9M | $90.7M | $66.4M | $96.8M |
| Depreciation and amortization | $130.7M | $111M | $98.8M | $92M | $81.4M |
| Stock-based compensation | $23.2M | $24.8M | $23.3M | $21M | $16.2M |
| Change in working capital | -$-120.42M | -$-54.62M | -$-52.3M | -$-75.85M | -$-47.74M |
| Accounts receivable | -$-89.66M | -$-24.98M | -$-21.08M | -$-41.38M | -$-17.54M |
| Inventory | -$-2.58M | -$-18.08M | -$-30.18M | -$-56.72M | $4.7M |
| Accounts payable | -$-570K | -$-16.62M | -$-520K | $26M | $19.5M |
| Net cash provided by operating activities | $196.2M | $205.2M | $180.2M | $116.4M | $156.7M |
| Investments in property, plant and equipment | -$-91.03M | -$-105.36M | -$-119.94M | -$-74.73M | -$-53.46M |
| Acquisitions, net | -$-178.87M | -$-138.54M | -$-43.6M | -$-126.64M | -$-217.98M |
| Net cash used for investing activities | -$-270.73M | -$-195.41M | -$-163.37M | -$-200.42M | -$-271M |
| Common stock issued | $3.64M | $740K | $0.00 | $0.00 | $0.00 |
| Common stock repurchased | -$-50.01M | $0.00 | -$-3.1M | -$-2.93M | -$-4.59M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | $43.6M | $13.3M | -$-18.01M | $92.5M | $82M |
| Net change in cash | -$-29.38M | $22.9M | -$-600K | $6.39M | -$-31.32M |
| Cash at end of period | $17.2M | $46.5M | $23.7M | $24.3M | $17.9M |
| Operating cash flow | $196.2M | $205.2M | $180.2M | $116.4M | $156.7M |
| Capital expenditure | -$-91.03M | -$-105.36M | -$-119.94M | -$-74.73M | -$-53.46M |
| Free cash flow | $105.1M | $99.9M | $60.3M | $41.7M | $103.2M |
Line items
Line items
Line items
About Integer Holdings Corporation
Integer Holdings Corporation functions as a global leader in outsourced medical device manufacturing, maintaining operations across the United States, Puerto Rico, Costa Rica, and other international regions. The company organizes its business into two primary divisions: Medical and Non-Medical. Within its Medical segment, Integer delivers a broad array of devices and components essential for numerous advanced medical procedures. These solutions cater to areas such as interventional cardiology, structural heart conditions, heart failure management, peripheral and neurovascular interventions, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, urology, and gastroenterology. Their extensive product portfolio includes cardiac rhythm management devices like implantable pacemakers, defibrillators, cardiac monitors, leads, and heart failure therapies. They also produce neuromodulation devices, such as implantable spinal cord stimulators, alongside critical components like non-rechargeable batteries, feedthroughs, device enclosures, precision-machined parts, and lead sub-assemblies. Furthermore, Integer provides rechargeable battery systems and chargers. A comprehensive range of surgical instruments and components is also offered for arthroscopic, laparoscopic, and general surgery, encompassing items like harmonic scalpels, various blades and shavers, radio frequency and biopsy probes, trocars, electrocautery components, wound dressings, GERD treatment parts, and phacoemulsification needles. Orthopedic offerings comprise specialized instruments for hip, knee, and spine surgeries, including reamers and chisels, among other general medical technologies. The Non-Medical segment concentrates on developing customized battery power and management systems, along with specialized battery solutions, designed for the energy, military, and environmental sectors. Integer primarily collaborates with multinational original equipment manufacturers (OEMs) and their affiliated subsidiaries, supporting their requirements across diverse markets, including cardiac, neuromodulation, orthopedics, vascular, advanced surgical, and portable medical applications. Established in 1970, Integer Holdings Corporation is headquartered in Plano, Texas.
- CEO
- Payman Khales
- Employees
- 11K
- Beta
- 0.64
Included in
Explore
Frequently asked questions
What is the intrinsic value of Integer Holdings Corporation (ITGR)?
Integer Holdings Corporation (ITGR) is currently strongly overvalued based on the InvestorsCraft IC model — IC value is more than 50% below the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is ITGR undervalued?
ITGR trades at a price of $126.97 (Nov 21, 2026): strongly overvalued — IC value is more than 50% below the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.